Ajanta Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


43,369	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
663	663	614	460	840
212	212	2.6	1.5	1.4
42,917	—	—	—	—
−451	−451	−611	−458	−839
₹3,423.81	—	—	—	—

4,739	4,739	3,793	3,569	3,389
4.5%	4.5%	0.1%	0.0%	0.0%
0.00×	—	—	—	—

7.43×	—	—	—	—
29.25×	—	—	—	—
33.25×	—	—	—	—
261.64×	—	—	—	—
5,776	5,453	4,648	4,209	3,743
1,467	1,395	1,260	1,172	783
1,291	1,222	1,115	1,037	652
—	529	1,157	785	792
164	164	839	633	617
—	161	835	632	617
—	365	318	152	174

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,369 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	43,368.6
- Cash, Equiv & ST Investments	840.1	459.5	613.8	663.1	663.1
+ Total Debt	1.4	1.5	2.6	212.0	212.0
Enterprise Value	—	—	—	—	42,917.5
Net Debt (memo)	-838.7	-458.1	-611.2	-451.1	-451.1
EV per Share	—	—	—	—	3,423.81

Total Capital	3,389.4	3,568.9	3,792.9	4,739.1	4,739.1
Total Debt/Total Capital	0.04	0.04	0.07	4.47	4.47
Total Debt/EV	—	—	—	—	0.00

EV/Sales	—	—	—	—	7.43
EV/EBITDA	—	—	—	—	29.25
EV/EBIT	—	—	—	—	33.25
EV/Free Cash Flow	—	—	—	—	261.64
Reference Items — Trailing FY Values
Sales	3,742.6	4,208.7	4,648.1	5,452.9	5,776.2
EBITDA	783.3	1,171.9	1,259.5	1,394.8	1,467.1
EBIT	652.5	1,036.5	1,115.4	1,221.7	1,290.7
Operating Cash Flow	791.8	785.1	1,157.2	529.2	—
Free Cash Flow	617.3	632.7	839.3	164.0	164.0
FCFF (free cash flow to the firm)	616.8	631.7	835.4	161.0	—
Capital Expenditure	174.5	152.4	317.9	365.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.